EphA5 Protein, a Potential Marker for Distinguishing Histological Grade and Prognosis in Ovarian Serous Carcinoma

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2016 Nov 27

PMID 27887627

Citations 8

Authors

Xiao Chen

Xuan Wang

Xue Wei

Jiandong Wang

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy. Disregulation of Eph/ephrin signaling has been implicated in oncogenesis and tumor progression. EphA5 receptor is one of large families of Eph tyrosine kinase receptor and is documented in the development of nervous system. Till now, there is no published data about the role of EphA5 in ovarian epithelial neoplasmas.

Methods: This study aims to investigate the expression of EphA5 protein in ovarian serous carcinoma, and its relationship to clinical pathological characteristics. Sixty-one cases of ovarian serous carcinoma, 24 cases of benign ovarian serous tumors, 42 cases of serous borderline tumors and 20 cases of normal fallopian tubes were examined using immunohistochemical staining. The relationship between EphA5 expression and pathological parameters was analyzed. Kaplan-Meier survival function was used to analyze prognosis of patients.

Results: Immunostaining analysis demonstrated that the EphA5 protein was highly expressed in 100% (20/20) of normal fallopian tube samples, 100% (24/24) of benign epithelial ovarian tumors, 76% (32/42) of ovarian serous borderline tumors, and 31% (19/61) of ovarian serous carcinomas. Loss of EphA5expression was associated with tumor grade (P < 0.001) and FIGO stage (P = 0.005). The survival analysis showed that patients with negative or weak expression of EphA5 protein had a poor outcome than those with positive expression (P = 0.004).

Conclusions: Our results show that EphA5 may be a potential biomarker for distinguishing high-and low-grade ovarian serous carcinoma and a potential prognostic marker.

Citing Articles

Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node.

Xia Y, Huang Y, Liu Z, Song S, Wang Y, Luo J Front Immunol. 2025; 16:1548102.

PMID: 39925800 PMC: 11802514. DOI: 10.3389/fimmu.2025.1548102.

Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers.

Lavareze L, Kimura T, Scarini J, de Lima-Souza R, Goncalves M, Sales de Sa R Front Oncol. 2025; 14:1520306.

PMID: 39839790 PMC: 11746119. DOI: 10.3389/fonc.2024.1520306.

The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management.

Psilopatis I, Pergaris A, Vrettou K, Tsourouflis G, Theocharis S Int J Mol Sci. 2022; 23(6).

PMID: 35328669 PMC: 8949008. DOI: 10.3390/ijms23063249.

Using MMRFBiolinks R-Package for Discovering Prognostic Markers in Multiple Myeloma.

Settino M, Cannataro M Methods Mol Biol. 2021; 2401:289-314.

PMID: 34902136 DOI: 10.1007/978-1-0716-1839-4_19.

The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread.

Pergaris A, Danas E, Goutas D, Sykaras A, Soranidis A, Theocharis S Int J Mol Sci. 2021; 22(16).

PMID: 34445116 PMC: 8395090. DOI: 10.3390/ijms22168412.

References

Singh N, Ayhan A, Menon U, Chin Aleong J, Faruqi A, Gayther S . Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. Histopathology. 2007; 52(3):393-5. DOI: 10.1111/j.1365-2559.2007.02912.x. View

ONeill C, Deavers M, Malpica A, Foster H, McCluggage W . An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005; 29(8):1034-41. View

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira V, Lopes C . Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol. 2004; 35(6):663-9. DOI: 10.1016/j.humpath.2004.01.024. View

Caras I . A link between axon guidance and axon fasciculation suggested by studies of the tyrosine kinase receptor EphA5/REK7 and its ligand ephrin-A5/AL-1. Cell Tissue Res. 1997; 290(2):261-4. DOI: 10.1007/s004410050930. View

Yamada T, Yuasa M, Masaoka T, Taniyama T, Maehara H, Torigoe I . After repeated division, bone marrow stromal cells express inhibitory factors with osteogenic capabilities, and EphA5 is a primary candidate. Bone. 2013; 57(2):343-54. DOI: 10.1016/j.bone.2013.08.028. View

Sherman-Baust C, Kuhn E, Valle B, Shih I, Kurman R, Wang T . A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol. 2014; 233(3):228-37. PMC: 4149901. DOI: 10.1002/path.4353. View

Numachi Y, Yoshida S, Yamashita M, Fujiyama K, Toda S, Matsuoka H . Altered EphA5 mRNA expression in rat brain with a single methamphetamine treatment. Neurosci Lett. 2007; 424(2):116-21. DOI: 10.1016/j.neulet.2007.07.025. View

Kober P, Bujko M, Oledzki J, Tysarowski A, Siedlecki J . Methyl-CpG binding column-based identification of nine genes hypermethylated in colorectal cancer. Mol Carcinog. 2011; 50(11):846-56. DOI: 10.1002/mc.20763. View

Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z . Downregulation of EphA5 by promoter methylation in human prostate cancer. BMC Cancer. 2015; 15:18. PMC: 4307617. DOI: 10.1186/s12885-015-1025-3. View

10.

Mamiya P, Hennesy Z, Zhou R, Wagner G . Changes in attack behavior and activity in EphA5 knockout mice. Brain Res. 2008; 1205:91-9. PMC: 4042433. DOI: 10.1016/j.brainres.2008.02.047. View

11.

Wu Y, Xu M, Wang L, Sun B, Gu G . Analysis of EphA5 receptor in the developing rat brain: an in vivo study in congenital hypothyroidism model. Eur J Pediatr. 2013; 172(8):1077-83. DOI: 10.1007/s00431-013-2008-5. View

12.

Gu Y, Li F, Qian N, Chen X, Wang H, Wang J . Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. J Clin Pathol. 2015; 69(5):448-53. DOI: 10.1136/jclinpath-2015-203160. View

13.

Fu D, Wang Z, Wang B, Chen L, Yang W, Shen Z . Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol. 2009; 41(1):48-58. DOI: 10.1016/j.humpath.2009.06.007. View

14.

St John J, Tisay K, Caras I, Key B . Expression of EphA5 during development of the olfactory nerve pathway in rat. J Comp Neurol. 2000; 416(4):540-50. DOI: 10.1002/(sici)1096-9861(20000124)416:4<540::aid-cne9>3.3.co;2-p. View

15.

Bodurka D, Deavers M, Tian C, Sun C, Malpica A, Coleman R . Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2011; 118(12):3087-94. PMC: 11809296. DOI: 10.1002/cncr.26618. View

16.

Bhagat R, Premalata C, Shilpa V, Pallavi V, Ramesh G, Vijay C . Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma. Tumour Biol. 2013; 34(4):2459-68. DOI: 10.1007/s13277-013-0797-9. View

17.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M . Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015; 41(2):136-43. DOI: 10.1016/j.ctrv.2014.12.003. View

18.

Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Dimakopoulou K . Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res. 2009; 16(2):267-76. DOI: 10.1007/s12253-009-9221-6. View

19.

Petkova T, Seigel G, Otteson D . A role for DNA methylation in regulation of EphA5 receptor expression in the mouse retina. Vision Res. 2010; 51(2):260-8. PMC: 3024446. DOI: 10.1016/j.visres.2010.09.022. View

20.

Cheon D, Tong Y, Sim M, Dering J, Berel D, Cui X . A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2013; 20(3):711-23. PMC: 3946428. DOI: 10.1158/1078-0432.CCR-13-1256. View